OMGA — Omega Therapeutics Share Price
0.000.00%
Last trade - 00:00- $132.37m
- $77.83m
- $3.09m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.28 | ||
| Price to Tang. Book | 2.28 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 42.78 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -56.47% | ||
| Return on Equity | -118.82% | ||
| Operating Margin | -3240.5% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 2.07 | 3.09 | 4.04 | 0.8 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in the development of a programmable epigenomic mRNA medicine to treat or cure a broad range of diseases. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The Company designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.
Directors
- Noubar Afeyan CHM (59)
- Mahesh Karande PRE (48)
- Roger Sawhney CFO (51)
- Thomas McCauley CSO (52)
- Yan Moore OTH (55)
- David Berry IND (43)
- Luke Beshar IND (63)
- Elliott Levy IND (62)
- John Mendlein IND (61)
- Mary Szela IND (58)
- Richard Young IND (67)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 13th, 2016
- Public Since
- July 30th, 2021
- No. of Shareholders
- 79
- No. of Employees
- 93
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 55,154,985
- Address
- 140 First Street, Suite 501, CAMBRIDGE, 02141
- Web
- https://omegatherapeutics.com/
- Phone
- +1 6179494360
- Auditors
- Deloitte & Touche LLP
Upcoming Events for OMGA
Similar to OMGA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Omega Therapeutics share price?
As of Today at 19:16 UTC, shares in Omega Therapeutics are trading at $2.40. This share price information is delayed by 15 minutes.
How has the Omega Therapeutics share price performed this year?
Shares in Omega Therapeutics last closed at $2.40 and the price had moved by -72% over the past 365 days. In terms of relative price strength the Omega Therapeutics share price has underperformed the S&P500 Index by -76.7% over the past year.
What are the analyst and broker recommendations for Omega Therapeutics?
The overall consensus recommendation for Omega Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Omega Therapeutics dividend yield?
Omega Therapeutics does not currently pay a dividend.
Does Omega Therapeutics pay a dividend?
Omega Therapeutics does not currently pay a dividend.
When does Omega Therapeutics next pay dividends?
Omega Therapeutics does not currently pay a dividend.
How do I buy Omega Therapeutics shares?
To buy shares in Omega Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Omega Therapeutics?
As of the previous close price of $2.40, shares in Omega Therapeutics had a market capitalisation of $132.37m.
Where are Omega Therapeutics shares listed?
Here are the trading details for Omega Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: OMGA
What kind of share is Omega Therapeutics?
Based on an overall assessment of its quality, value and momentum Omega Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Omega Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Omega Therapeutics is $11.83. That is 392.92% above the last closing price of $2.40.
Analysts covering Omega Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.15 for the next financial year.
What is the trend in the Omega Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Omega Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +35.84%.
As of the last closing price of $2.40, shares in Omega Therapeutics were trading -25.66% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Omega Therapeutics PE Ratio?
The Omega Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Omega Therapeutics?
Omega Therapeutics' management team is headed by:
- Noubar Afeyan - CHM
- Mahesh Karande - PRE
- Roger Sawhney - CFO
- Thomas McCauley - CSO
- Yan Moore - OTH
- David Berry - IND
- Luke Beshar - IND
- Elliott Levy - IND
- John Mendlein - IND
- Mary Szela - IND
- Richard Young - IND